Lupin gets FDA nod for oral contraceptive

Tags: News
Mumbai-headquartered Lupin has received approval from food and drugs administration (USFDA) to sell generic version of Watson Laboratories’ Lutera tablets. Lutera is an oral contraceptive drug.

The move will help company strengthen its oral contraceptive product basket. It is Lupin’s seventh oral contraceptive product approved by the USFDA. US is the largest drug market in the world and accounts for about one-third of volumes for the company. Oral contraceptive is less competed for segment. There are just three players in the market for this product: Vintage, Teva and Watson. Lupin’s has filed 32 products in the oral contraceptive segment with the FDA and waiting for approval.

Lupin’s levonorgestrel and ethinyl estradiol tablets, having strength of 0.1 mg and 0.02 mg, are combined oral contraceptives prescribed for the prevention of pregnancy in women who choose to use oral contraceptives as a method of avoiding pregnancy.

“Lutera had annual US sales of approximately $103.6 million. Lupin will be marketing its generic product shortly,” said a company statement. The generic market for oral contraceptives is estimated at $1.2 billion.

Last month, Lupin received approval from USFDA for its oral contraceptive drug Yasmin that had annual sales of $275 million in the US.

In the quarter that ended September 30 Lupin reported consolidated revenue of Rs 2,301 crore with net profit of Rs 290 crore. The company is expected to declare its quarterly result on January 31.

shutiverma@mydigitalfc.com

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Those willfully defaulting on loans should be blacklisted by Sebi

    As reported by this newspaper’s Monday edition, the Securities and Exchange Board of India (Sebi) has found merit in the Reserve Bank of India’s s

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Arun Kumar Jain

Kickstarting technological innovation

One of the key dimensions of global competitiveness is the ...

Kuruvilla Pandikattu SJ

Developing moral, spiritual capacity

Writing in The Huffington Post, Noam Chomsky, professor emeritus, MIT ...

Gautam Gupta

Manufacturing must keep workers’ welfare in mind

It may be early days yet, but the labour reforms ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture